Piper Sandler Issues Pessimistic Forecast for Axon Enterprise (NASDAQ:AXON) Stock Price

Axon Enterprise (NASDAQ:AXON) had its price target reduced by equities researchers at Piper Sandler from $893.00 to $753.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s target price would suggest a potential upside of 23.56% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Axon Enterprise in a research note on Wednesday, October 8th. Raymond James Financial reaffirmed an “outperform” rating and issued a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. JMP Securities reissued a “market outperform” rating and set a $825.00 price target on shares of Axon Enterprise in a report on Monday, September 29th. JPMorgan Chase & Co. upped their price objective on Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research note on Thursday, July 17th. Finally, Bank of America lifted their target price on Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $831.64.

Axon Enterprise Stock Down 13.7%

Shares of NASDAQ:AXON traded down $96.70 during trading hours on Wednesday, reaching $609.43. The stock had a trading volume of 2,031,414 shares, compared to its average volume of 675,115. Axon Enterprise has a 1 year low of $450.72 and a 1 year high of $885.91. The firm’s 50 day moving average is $729.01 and its 200-day moving average is $736.07. The stock has a market capitalization of $47.84 billion, a price-to-earnings ratio of 150.48, a P/E/G ratio of 29.49 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). The business had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.Axon Enterprise’s revenue was up 30.6% on a year-over-year basis. During the same period last year, the business posted $1.45 EPS. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts predict that Axon Enterprise will post 5.8 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other news, Director Jeri Williams sold 100 shares of the stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the completion of the transaction, the director owned 1,416 shares in the company, valued at $1,065,596.64. This trade represents a 6.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the completion of the sale, the chief financial officer owned 93,592 shares of the company’s stock, valued at $66,813,456.96. This trade represents a 5.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 59,932 shares of company stock valued at $45,115,616. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors have recently made changes to their positions in the stock. Stone House Investment Management LLC acquired a new position in Axon Enterprise in the 3rd quarter valued at about $29,000. Hemington Wealth Management lifted its stake in shares of Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares during the period. Whipplewood Advisors LLC boosted its position in Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 27 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Axon Enterprise in the 2nd quarter worth approximately $37,000. Finally, Root Financial Partners LLC acquired a new position in Axon Enterprise in the 3rd quarter valued at $34,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.